IL322023A - Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus proteins and their use - Google Patents

Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus proteins and their use

Info

Publication number
IL322023A
IL322023A IL322023A IL32202325A IL322023A IL 322023 A IL322023 A IL 322023A IL 322023 A IL322023 A IL 322023A IL 32202325 A IL32202325 A IL 32202325A IL 322023 A IL322023 A IL 322023A
Authority
IL
Israel
Prior art keywords
seq
nanostructure
polypeptides
polypeptide
cavl
Prior art date
Application number
IL322023A
Other languages
English (en)
Hebrew (he)
Inventor
Neil P King
David Baker
Brooke Nickerson
Lance Joseph Stewart
Laurent Perez
Antonio Lanzavecchia
Jessica Marcandalli
Jorge Fallas
Yang Hsia
Original Assignee
Univ Washington
Institute For Res In Biomedicine Irb
Neil P King
David Baker
Brooke Nickerson
Lance Joseph Stewart
Laurent Perez
Antonio Lanzavecchia
Jessica Marcandalli
Jorge Fallas
Yang Hsia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Institute For Res In Biomedicine Irb, Neil P King, David Baker, Brooke Nickerson, Lance Joseph Stewart, Laurent Perez, Antonio Lanzavecchia, Jessica Marcandalli, Jorge Fallas, Yang Hsia filed Critical Univ Washington
Publication of IL322023A publication Critical patent/IL322023A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL322023A 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus proteins and their use IL322023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (1)

Publication Number Publication Date
IL322023A true IL322023A (en) 2025-09-01

Family

ID=62116943

Family Applications (2)

Application Number Title Priority Date Filing Date
IL322023A IL322023A (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus proteins and their use
IL26964319A IL269643A (en) 2017-04-04 2019-09-25 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL26964319A IL269643A (en) 2017-04-04 2019-09-25 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Country Status (24)

Country Link
US (4) US11192926B2 (https=)
EP (2) EP3606942B1 (https=)
JP (3) JP7168938B2 (https=)
KR (2) KR102774312B1 (https=)
CN (3) CN115779077A (https=)
AU (3) AU2018249533C1 (https=)
BR (1) BR112019020661A2 (https=)
CA (1) CA3058794A1 (https=)
DK (1) DK3606942T3 (https=)
ES (1) ES3040563T3 (https=)
FI (1) FI3606942T3 (https=)
HR (1) HRP20251060T1 (https=)
HU (1) HUE073526T2 (https=)
IL (2) IL322023A (https=)
LT (1) LT3606942T (https=)
MX (2) MX2019011869A (https=)
PH (1) PH12019502276A1 (https=)
PL (1) PL3606942T3 (https=)
PT (1) PT3606942T (https=)
RS (1) RS67190B1 (https=)
SG (1) SG11201908999QA (https=)
SI (1) SI3606942T1 (https=)
SM (1) SMT202500317T1 (https=)
WO (1) WO2018187325A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
CN114502572A (zh) * 2019-09-04 2022-05-13 华盛顿大学 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
CN115103682A (zh) * 2020-01-30 2022-09-23 摩登纳特斯有限公司 呼吸道病毒免疫组合物
BR112022016197A2 (pt) * 2020-02-14 2022-10-25 Univ Washington Polipeptídeos e seus usos
EP4103230A1 (en) * 2020-02-14 2022-12-21 University of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
MX2022015593A (es) * 2020-06-09 2023-04-03 Icosavax Inc Metodo de ensamblaje de particulas similares a virus de dos componentes.
AU2021286574A1 (en) * 2020-06-09 2023-01-19 Icosavax, Inc. Method of making virus-like particle
NZ798475A (en) 2020-10-09 2026-03-27 Univ Texas Prefusion-stabilized hmpv f proteins
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
JP2023549815A (ja) 2020-11-13 2023-11-29 アイコサバックス， インコーポレイテッド メタニューモウイルスのためのタンパク質ベースのナノ粒子ワクチン
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
IL310628A (en) * 2021-08-10 2024-04-01 Icosavax Inc Virus-like particle vaccine for respiratory syncytial virus
AU2023273041A1 (en) 2022-05-17 2024-12-05 Icosavax, Inc. Multivalent vaccine for paramyxoviruses and uses thereof
EP4626470A2 (en) * 2022-11-29 2025-10-08 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
WO2025017142A1 (en) * 2023-07-18 2025-01-23 Astrazeneca Ab Rsv vaccine
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
CN1133660C (zh) 1998-03-04 2004-01-07 埃克森美孚化学专利公司 烯烃的高温聚合方法
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
US20040214276A1 (en) 2002-07-31 2004-10-28 Chaitan Khosla Production of glycosylated macrolides in E. coli
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
PL2222710T3 (pl) 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
JP5813513B2 (ja) 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN103037898B (zh) 2010-07-07 2016-06-29 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
CA2813752A1 (en) * 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
US20130122032A1 (en) 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP2766030A4 (en) 2011-10-12 2015-09-16 Univ Washington MANIPULATED OUTER DOMAIN OF HV-GP120 AND MUTANTS THEREOF
CA2870182A1 (en) 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
ES2753138T3 (es) 2012-07-06 2020-04-07 Glaxosmithkline Biologicals Sa Complejos de proteínas de citomegalovirus
MY171498A (en) 2012-08-01 2019-10-15 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
EA201590683A1 (ru) 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Тримеры rsv f, предшествующие слиянию
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
FI2970398T3 (fi) 2013-03-13 2024-08-06 Us Health Rsv f -prefuusioproteiineja ja niiden käyttö
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖｆポリペプチド
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
US20150110825A1 (en) * 2013-09-24 2015-04-23 Massachusetts Institute Of Technology Self-assembled nanoparticle vaccines
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
CA2934472A1 (en) 2014-01-09 2015-07-16 Alpha-O Peptides Ag Flagellin-containing protein nanoparticles as a vaccine platform
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US10117925B2 (en) 2014-07-10 2018-11-06 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
US10501733B2 (en) 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2017027480A1 (en) 2015-08-13 2017-02-16 Echogen Power Systems, L.L.C. Heat engine system including an integrated cooling circuit
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
EP4494650A3 (en) 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
WO2017066484A2 (en) 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
TW201729835A (zh) 2015-10-22 2017-09-01 現代公司 呼吸道病毒疫苗
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
KR102774312B1 (ko) 2017-04-04 2025-03-05 유니버시티 오브 워싱톤 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
CA3095216A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Also Published As

Publication number Publication date
CA3058794A1 (en) 2018-10-11
PT3606942T (pt) 2025-09-01
US20200392187A1 (en) 2020-12-17
JP2024160321A (ja) 2024-11-13
PL3606942T3 (pl) 2025-11-12
LT3606942T (lt) 2025-10-10
HRP20251060T1 (hr) 2025-11-07
SI3606942T1 (sl) 2025-11-28
SG11201908999QA (en) 2019-10-30
KR20190140916A (ko) 2019-12-20
WO2018187325A1 (en) 2018-10-11
RU2019130167A (ru) 2021-05-05
US20220169681A1 (en) 2022-06-02
CN115947873A (zh) 2023-04-11
KR102774312B1 (ko) 2025-03-05
IL269643A (en) 2019-11-28
RU2019130167A3 (https=) 2021-12-22
AU2022202787B2 (en) 2024-07-04
MX2019011869A (es) 2020-01-09
AU2022202787A1 (en) 2022-05-19
PH12019502276A1 (en) 2020-09-28
EP4559869A3 (en) 2025-08-20
BR112019020661A2 (pt) 2020-05-05
AU2018249533A1 (en) 2019-10-17
JP7541701B2 (ja) 2024-08-29
MX2023004704A (es) 2023-05-09
JP2023002680A (ja) 2023-01-10
CN115779077A (zh) 2023-03-14
EP4559869A2 (en) 2025-05-28
US20250263445A1 (en) 2025-08-21
AU2018249533B2 (en) 2022-01-27
US11732011B2 (en) 2023-08-22
DK3606942T3 (da) 2025-09-08
ES3040563T3 (en) 2025-11-03
JP2020515280A (ja) 2020-05-28
AU2024220089A1 (en) 2024-10-17
US12275757B2 (en) 2025-04-15
AU2022202787C1 (en) 2025-01-30
KR20240161683A (ko) 2024-11-12
HUE073526T2 (hu) 2026-01-28
US20240150411A1 (en) 2024-05-09
SMT202500317T1 (it) 2025-11-10
JP7168938B2 (ja) 2022-11-10
AU2018249533C1 (en) 2023-10-12
RS67190B1 (sr) 2025-10-31
EP3606942A1 (en) 2020-02-12
US11192926B2 (en) 2021-12-07
FI3606942T3 (fi) 2025-08-29
EP3606942B1 (en) 2025-06-11
CN110603262A (zh) 2019-12-20

Similar Documents

Publication Publication Date Title
US12275757B2 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
TWI756828B (zh) Rsv f蛋白突變體
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
AU2021269783A1 (en) Stabilized coronavirus spike protein fusion proteins
JP2025172875A (ja) パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
HK40128177A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
HK40014567A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567B (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK1263007A1 (en) Rsv f protein mutants